Change in adrenal mass size as a predictor of a malignant tumor.

Kevin M. Pantalone, Thottathil Gopan, Erick M. Remer, Charles Faiman, Adriana G. Ioachimescu, Howard S. Levin, Allan Siperstein, Eren Berber, Laura B. Shepardson, Emmanuel L. Bravo, Amir Hamrahian

Research output: Contribution to journalArticle

Abstract

To assess the value of adrenal mass absolute growth, growth rate, and percentage growth rate on serial imaging for distinguishing benign from malignant adrenal masses. We retrospectively reviewed the Cleveland Clinic medical record data on 136 adrenalectomies or biopsies in 132 patients with 2 imaging studies performed more than 2 months apart (during 1997 to 2008). There were 111 benign (81.6%) and 25 malignant (18.4%) adrenal masses. With use of receiver operating characteristic curve analysis, all 3 aforementioned growth measures showed similar levels of discrimination for the entire study group as well as for the subgroups with 3 to 12 months of follow-up (n = 75 masses) and noncontrast computed tomography Hounsfield units >10 or not reported (n = 111 masses). After adjustment for other factors, the 3 growth measures remained statistically significant predictors of a malignant tumor. The absolute growth cutoff value of 0.8 cm had the highest sum of sensitivity and specificity of 72% and 81.1%, respectively. We could not identify an adrenal mass growth cutoff value to provide 100% sensitivity or specificity to confirm or exclude the presence of a malignant lesion. In 3 patients with metastatic lesions, no growth or a decrease in mass size during a period of 4 to 36 months was observed. In this study, the largest with surgical histopathology findings as the "gold standard" for diagnosis, change in adrenal mass size was a significant predictor of a malignant tumor. Nevertheless, we could not identify an adrenal mass growth cutoff value for reliable confirmation or exclusion of a malignant lesion. Change in adrenal mass size should be used in conjunction with other imaging and clinical characteristics when surgical resection is being considered.

Original languageEnglish (US)
Pages (from-to)577-587
Number of pages11
JournalEndocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
Volume16
Issue number4
DOIs
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

Growth
Neoplasms
Sensitivity and Specificity
Adrenalectomy
ROC Curve
Medical Records
Intercellular Signaling Peptides and Proteins
Tomography
Biopsy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Change in adrenal mass size as a predictor of a malignant tumor. / Pantalone, Kevin M.; Gopan, Thottathil; Remer, Erick M.; Faiman, Charles; Ioachimescu, Adriana G.; Levin, Howard S.; Siperstein, Allan; Berber, Eren; Shepardson, Laura B.; Bravo, Emmanuel L.; Hamrahian, Amir.

In: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, Vol. 16, No. 4, 01.01.2010, p. 577-587.

Research output: Contribution to journalArticle

Pantalone, KM, Gopan, T, Remer, EM, Faiman, C, Ioachimescu, AG, Levin, HS, Siperstein, A, Berber, E, Shepardson, LB, Bravo, EL & Hamrahian, A 2010, 'Change in adrenal mass size as a predictor of a malignant tumor.', Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, vol. 16, no. 4, pp. 577-587. https://doi.org/10.4158/EP09351.OR
Pantalone, Kevin M. ; Gopan, Thottathil ; Remer, Erick M. ; Faiman, Charles ; Ioachimescu, Adriana G. ; Levin, Howard S. ; Siperstein, Allan ; Berber, Eren ; Shepardson, Laura B. ; Bravo, Emmanuel L. ; Hamrahian, Amir. / Change in adrenal mass size as a predictor of a malignant tumor. In: Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2010 ; Vol. 16, No. 4. pp. 577-587.
@article{96e738f9278943d4b2891bcd96709f7d,
title = "Change in adrenal mass size as a predictor of a malignant tumor.",
abstract = "To assess the value of adrenal mass absolute growth, growth rate, and percentage growth rate on serial imaging for distinguishing benign from malignant adrenal masses. We retrospectively reviewed the Cleveland Clinic medical record data on 136 adrenalectomies or biopsies in 132 patients with 2 imaging studies performed more than 2 months apart (during 1997 to 2008). There were 111 benign (81.6{\%}) and 25 malignant (18.4{\%}) adrenal masses. With use of receiver operating characteristic curve analysis, all 3 aforementioned growth measures showed similar levels of discrimination for the entire study group as well as for the subgroups with 3 to 12 months of follow-up (n = 75 masses) and noncontrast computed tomography Hounsfield units >10 or not reported (n = 111 masses). After adjustment for other factors, the 3 growth measures remained statistically significant predictors of a malignant tumor. The absolute growth cutoff value of 0.8 cm had the highest sum of sensitivity and specificity of 72{\%} and 81.1{\%}, respectively. We could not identify an adrenal mass growth cutoff value to provide 100{\%} sensitivity or specificity to confirm or exclude the presence of a malignant lesion. In 3 patients with metastatic lesions, no growth or a decrease in mass size during a period of 4 to 36 months was observed. In this study, the largest with surgical histopathology findings as the {"}gold standard{"} for diagnosis, change in adrenal mass size was a significant predictor of a malignant tumor. Nevertheless, we could not identify an adrenal mass growth cutoff value for reliable confirmation or exclusion of a malignant lesion. Change in adrenal mass size should be used in conjunction with other imaging and clinical characteristics when surgical resection is being considered.",
author = "Pantalone, {Kevin M.} and Thottathil Gopan and Remer, {Erick M.} and Charles Faiman and Ioachimescu, {Adriana G.} and Levin, {Howard S.} and Allan Siperstein and Eren Berber and Shepardson, {Laura B.} and Bravo, {Emmanuel L.} and Amir Hamrahian",
year = "2010",
month = "1",
day = "1",
doi = "10.4158/EP09351.OR",
language = "English (US)",
volume = "16",
pages = "577--587",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "4",

}

TY - JOUR

T1 - Change in adrenal mass size as a predictor of a malignant tumor.

AU - Pantalone, Kevin M.

AU - Gopan, Thottathil

AU - Remer, Erick M.

AU - Faiman, Charles

AU - Ioachimescu, Adriana G.

AU - Levin, Howard S.

AU - Siperstein, Allan

AU - Berber, Eren

AU - Shepardson, Laura B.

AU - Bravo, Emmanuel L.

AU - Hamrahian, Amir

PY - 2010/1/1

Y1 - 2010/1/1

N2 - To assess the value of adrenal mass absolute growth, growth rate, and percentage growth rate on serial imaging for distinguishing benign from malignant adrenal masses. We retrospectively reviewed the Cleveland Clinic medical record data on 136 adrenalectomies or biopsies in 132 patients with 2 imaging studies performed more than 2 months apart (during 1997 to 2008). There were 111 benign (81.6%) and 25 malignant (18.4%) adrenal masses. With use of receiver operating characteristic curve analysis, all 3 aforementioned growth measures showed similar levels of discrimination for the entire study group as well as for the subgroups with 3 to 12 months of follow-up (n = 75 masses) and noncontrast computed tomography Hounsfield units >10 or not reported (n = 111 masses). After adjustment for other factors, the 3 growth measures remained statistically significant predictors of a malignant tumor. The absolute growth cutoff value of 0.8 cm had the highest sum of sensitivity and specificity of 72% and 81.1%, respectively. We could not identify an adrenal mass growth cutoff value to provide 100% sensitivity or specificity to confirm or exclude the presence of a malignant lesion. In 3 patients with metastatic lesions, no growth or a decrease in mass size during a period of 4 to 36 months was observed. In this study, the largest with surgical histopathology findings as the "gold standard" for diagnosis, change in adrenal mass size was a significant predictor of a malignant tumor. Nevertheless, we could not identify an adrenal mass growth cutoff value for reliable confirmation or exclusion of a malignant lesion. Change in adrenal mass size should be used in conjunction with other imaging and clinical characteristics when surgical resection is being considered.

AB - To assess the value of adrenal mass absolute growth, growth rate, and percentage growth rate on serial imaging for distinguishing benign from malignant adrenal masses. We retrospectively reviewed the Cleveland Clinic medical record data on 136 adrenalectomies or biopsies in 132 patients with 2 imaging studies performed more than 2 months apart (during 1997 to 2008). There were 111 benign (81.6%) and 25 malignant (18.4%) adrenal masses. With use of receiver operating characteristic curve analysis, all 3 aforementioned growth measures showed similar levels of discrimination for the entire study group as well as for the subgroups with 3 to 12 months of follow-up (n = 75 masses) and noncontrast computed tomography Hounsfield units >10 or not reported (n = 111 masses). After adjustment for other factors, the 3 growth measures remained statistically significant predictors of a malignant tumor. The absolute growth cutoff value of 0.8 cm had the highest sum of sensitivity and specificity of 72% and 81.1%, respectively. We could not identify an adrenal mass growth cutoff value to provide 100% sensitivity or specificity to confirm or exclude the presence of a malignant lesion. In 3 patients with metastatic lesions, no growth or a decrease in mass size during a period of 4 to 36 months was observed. In this study, the largest with surgical histopathology findings as the "gold standard" for diagnosis, change in adrenal mass size was a significant predictor of a malignant tumor. Nevertheless, we could not identify an adrenal mass growth cutoff value for reliable confirmation or exclusion of a malignant lesion. Change in adrenal mass size should be used in conjunction with other imaging and clinical characteristics when surgical resection is being considered.

UR - http://www.scopus.com/inward/record.url?scp=79952010763&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952010763&partnerID=8YFLogxK

U2 - 10.4158/EP09351.OR

DO - 10.4158/EP09351.OR

M3 - Article

C2 - 20150023

AN - SCOPUS:79952010763

VL - 16

SP - 577

EP - 587

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 4

ER -